| Biaxin xl clarithromycin
Violates the synthesis of microbial protein (binds to the 50S subunit of the ribosome membrane microbial cells). It works on the extra- and intracellular pathogens located. Active against: Staphylococcus spp, Streptococcus agalactiae (Streptococcus pyogenes, Streptococcus viridans, Streptococcus pneumoniae), Haemophilus influenzae (Haemophilus parainfluenzae), Haemophilus ducreyi, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Legionella pneumophila, Mycoplasma pneumoniae, Helicobacter pylori (Campylobacter. ), Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Moraxella catarrhalis, Bordetella pertussis, Propionibacterium acne, Mycobacterium avium, Mycobacterium leprae, Mycobacterium kansasii, Mycobacterium marinum, Staphylococcus aureus, Ureaplasma urealyticum, Toxoplasma gondii, Corynebacterium spp., Borrelia burgdorferi, Pasteurella multocida , certain anaerobes (Eubacter spp., Peptococcus spp., Propionibacterium spp., Clostridium perfringens, Bacteroides melaninogenicus), is less active against Micobacterium tuberculosis.
Biaxin xl clarithromycin
Absorption - fast. Food delays absorption, not significantly affecting bioavailability. Communication with plasma proteins - more than 90%. After a single dose Cmax peak recorded 2. The second peak is due to the ability of the drug to concentrate in the gall bladder and then enters the intestine and absorption. Cmax after oral administration of 250 mg is achieved in 1-3 hours.
After oral administration, 20% of the dose rapidly hydroxylated in the liver enzyme cytochrome P450 CYP3A4, CYP3A5 and CYP3A7 with the formation of the major metabolite - 14 hydroxyclarithromycin having pronounced antimicrobial activity against Haemophilus influenzae. It is an inhibitor of isozymes CYP3A4, CYP3A5 and CYP3A7.
Biaxin xl clarithromycin
With regular use of 250 mg / day equilibrium concentrations of the unchanged drug and its major metabolite - 1 and 0.6 ug / ml, respectively; T1 / 2 - 4.3 and 5.6 hours, respectively. When increasing the dose to 500 mg / day equilibrium concentration of the unchanged drug and its metabolite in plasma - 0,83-0,88 and 2.7-2.9 ug / ml, respectively; T1 / 2 - 4,8-5 and 6,9-8,7 hours, respectively. At therapeutic concentrations accumulate in the lungs, skin and soft tissues (which is 10 times higher than a serum level concentration).
Excreted by the kidneys and feces (20-30% - in unmodified form, the rest - in the form of metabolites). In single dose of 250 mg and 1200 allocated 37.9 kidneys and 46% with faeces - 40.2 and 29.1%, respectively.
|